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The participation of interferon-y in activation of murine macrophages for tumor cell lysis 
was investigated. Biochemically macrophage activation factor and interferon-y have not been 
separated. Antiviral titers correlated closely with macrophage activation in antigen- or mitogen- 
induced spleen cell supematants. A monoclonal rat antibody that neutralized virus-induced 
interferon was also found to neutralize interferon-y in such supematants. These monoclonal 
antibodies were coupled to CH-Sepharose 4B and used for absorption of antiviral activity from 
mitogen-induced spleen cell supematants. Absorption of the interferon was paralleled by the 
reduction of the macrophage-activating capacity of the supematants. Data from control absorptions 
supported the specificity of the absorption effect. These results indicate that interferon-y is 
required for activation of macrophages for tumor cell lysis. These results can be interpreted in 
two ways: (a) the monoclonal antibodies cross-react with interferon-r and with a mediator that 
is required for activation of macrophages for tumor cell lysis or (b) interferon-y itself is an 
essential cofactor for macrophage activation. 
INTRODUCTION 
Evidence for a prominent role of interferons in modulating macrophage antitumor 
function has been extensively described (reviewed in (1)). Nonspecific tumoricidal 
activity was induced in macrophages utilizing semipurified fibroblast interferon (IFN) 
preparations (2, 3). Of these IFN ((Y and @) preparations lo3 units/ml of culture 
medium were necessary for significant activation of macrophages. The mechanism 
of activation of IFN (o and /3) seems to be qualitatively and quantitatively different 
from that of macrophage-activating factor (MAF) obtained from antigen- or mitogen- 
induced spleen cell supematants (3,4). On the other hand, striking similarities between 
MAF and another type of interferon, IFN-y, in physicochemical characteristics and 
coordinate production have been observed (5). Physicochemical separation of MAF 
and IFN-y has not yet been achieved. Also, cloned T cells and T-cell hybridomas 
were reported to be producer cells for both IFN-7 and MAF activity (6-8). 
In this report a different approach for evaluation of the function of EN--r in 
macrophage activation is described. Monoclonal rat antibodies with inhibitory capacity 
for antiviral activity were tested for their effects on macrophage activation by MAF- 
containing lymphokines. 
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MATERIALS AND METHODS 
Mice. Male CsH/Tif, 6 to 12 weeks of age, were purchased from Bomholtgard, 
Ry, Denmark. Female LOU rats were obtained from R. Kemler, F. Miescher Institute, 
Tubingen, West Germany. 
Lymphokine preparations. Concanavalin A (ConA) supernatants were prepared by 
culturing 10’ spleen cells/ml culture medium (RPM1 1640, GIBCO) + 10% heat- 
inactivated FCS + 50 pg gentamicin (Sigma)/ml for 24 hr in the presence of 5 pg 
ConA (Pharmacia)/ml at 37°C in 5% CO2 in moist air. cY-Methyl-Dmannoside (Carl 
Roth KG, Karlsruhe, West Germany) was added to the cell-free supematants to a 
concentration of 1 mM. For antigen-stimulated spleen cell supematants mice were 
immunized intraperitoneally (ip) with 5 X lo6 viable Mycobacterium bovis, strain 
BCG (Phipps substrain, TMC 1029, Trudeau Mycobacterial Collection, Saranac 
Lake, N.Y.) and 3 weeks after immunization 5 X lo6 spleen cells/ml culture medium 
were cultured with 50 to 100 pg of purified protein derivative/ml (PPD, Connought 
Medical Research Laboratories, Toronto, Canada) for 48 hr at 37°C in 5% CO2 in 
moist air. Cell free supematants were stored at -20°C until used. 
Assay for interferon activity. Interferon titrations were performed by using a mi- 
crotiter assay with L929 cells (0.2 ml of medium (RPM1 1640 + 5% FCS) per well) 
and vesicular stomatitis virus (Indiana strain) as challenge virus. One unit corresponds 
to the minimal amount of interferon capable of conferring protection to 50% of the 
cells. One microtiter unit/O.2 ml corresponds to 2 NIH reference units/ml. All titers 
are expressed in laboratory units. 
Assayfir interleukin 2 activity. The amount of interleukin 2 (IL-2) in supematants 
was measured by their ability to support the growth of the IL-2 dependent cell line 
W-2 (9). Thymidine incorporation after a 20-hr incubation and a 4-hr pulse with 0.5 
&i of [methyl-3H]thymidine ([3H]TdR, sp act 50 Ci/mmol, Amersham International 
Ltd, Amersham, U.K.) was determined. Results are expressed as laboratory units as 
described by Gillis et al. (10). 
Assay for macrophage cytotoxic activity. The detailed protocol of the cytotoxicity 
assay was described earlier (11). Mice were treated ip 1 day previously with 1 ml of 
phosphate-buffered salaine (PBS). Peritoneal exudate cells (PEC) were collected after 
ip injection of 10 ml of Dulbecco’s minimal essential medium (DMEM) containing 
10% heat-inactivated FCS and 50 pg of gentamicin/ml. Peritoneal fluid was withdrawn 
through the anterior wall with a 1Pgauge needle. Fluids were pooled and a sample 
was taken for differential and total cell counts, and the remainder was centrifuged 
in polypropylene tubes (2074, Falcon Plastics) at 2508 for 10 min. Differential counts 
were made on Wright-stained cell smears prepared by cytocentrifugation (Cytospin 
centrifuge, Shandon Southern Instruments, Camberley, U.K.). Washed PEC suspen- 
sions were adjusted to 12 X lo5 macrophages/ml DMEM ( 10% FCS, gentamicin) 
and 0.1 ml of the cell suspension per flat-bottom well of a 96-well tissue culture 
cluster (Costar 3596) was incubated at 37°C in 5% CO* in moist air. Macrophages 
were exposed to dilutions of lymphokine supematants as adherent PEC for 5 hr at 
37°C in 5% CO* in moist air or continuously during the 48-hr culture period. [3H]TdR- 
prelabeled tumor target cells ( 1023) (3-methylcholanthrene-induced fibrosarcoma of 
C3H/HeN origin) were obtained from washed and trypsin-digested cell monolayers. 
TWO to three million adherent cells in 20 ml of DMEM (10% FCS, gentamicin) were 
labeled with 1 &i of [3H]TdR/ml (sp act 5 Ci/mmol, Amersham International Ltd) 
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for 20 hr at 37°C in 5% CO2 in moist air. Six thousand tumor cells were added to 
the PEC in a total volume of 0.2 ml of DMEM (10% FCS, gentamicin). After 48 hr, 
labeled tumor cell monolayers lysed with 0.5% SDS in water were used to estimate 
total incorporated counts. Cytotoxicity was estimated by measurement of [3H]TdR 
release from prelabeled tumor cells in triplicate cultures and expressed as percentage 
of SDS total counts _+ SD or as specific cytotoxicity according to the formula: 
100x 
experimental cpm - background cpm 
total incorporated cpm - background cpm > ’ 
IgG preparation from rat hybridomas. For mass production of antibodies 5 X lo6 
rat hybridoma cells secreting monoclonal IgG directed against murine IFN ( 12) were 
injected ip into adult female rats (LOU) that had received 2 ml of Pristan mineral 
oil (Carl Roth KG, Karlsruhe, West Germany) ip 1 week previously. One to two 
weeks later, ascites fluid was recovered from the peritoneal cavity and IgG purified 
by ammonium sulfate precipitation (45% saturated) followed by gel filtration on 
Sephacryl-S300. 
Coupling of IgG to activated CH-Sepharose 4B. Per 4 g activated CH-Sepharose 
4B (Pharmacia) 20 mg of commercial rat IgG or monoclonal IgG from 20 ml ascites 
fluid was mixed in bicarbonate buffer 0.1 M, pH 8, containing 0.5 A4 NaCl, for 1 hr 
at room temperature. Free binding sites were saturated with ethanolamine 1 &f, pH 
9, and the immunosorbent was washed with five cycles of 0.1 A$ formate buffer, pH 
4, containing NaCl (0.5 M) and Tris buffer 0.1 M, pH 8, also containing NaCl 
(0.5 M). 
RESULTS 
Correlation of Antiviral Titer and MAF Activity 
Spleen cell suspensions from individual mice infected with BCG were challenged 
in vitro with PPD. The supematants of these cultures were tested for both their 
antiviral and macrophage-activating capacities. In all tested samples of over 40 lym- 
phokines from individual mice the activating capacity correlated very well with the 
IFN titer of the preparation. Figure 1 shows the correlation of antiviral titers and 
macrophage cytotoxicity obtained from one experiment in which 10 of these lym- 
phokines were tested. From these results one can calculate that a final concentration 
of less than 10 international units of immune IFN was sufficient for significant mac- 
rophage activation. In addition, earlier reports on pH 2 lability of macrophage-ac- 
tivating factor (MAF) ( 13) and IFN-y (14,15) were confirmed with these lymphokines 
(data not shown). 
Neutralization of IFN-y Activity by Monoclonal Antibodies 
A monoclonal rat antibody that neutralized virus-induced interferon was described 
earlier (12). IgG of this clone was purified from ascites fluid by ammonium sulfate 
precipitation followed by gel filtration on Sephacryl-S300. Table 1 shows that the 
monoclonal antibodies not only reduced the antiviral titer of virus-induced interferon, 
but also inhibited two different IFN-7 preparations in a dose-dependent manner. 
Commercial rat IgG at the same concentration had no inhibitory effect. IFN-r activity 
was destroyed at pH 2 and not neutralized by a sheep antivirus-induced IFN antiserum 
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FIG. 1. Correlation of antiviral and macrophage-activating activities in lymphokines. The antiviral titers 
of IO mitogen-induced lymphokine preparations were plotted versus the concentration of these lymphokines 
that resulted in l/2 maximal tumor cytotoxicity in one experiment. 
that completely neutralized the virus-induced IFN (data not shown). Thus, the mono- 
clonal rat IgG besides reacting with all molecular weight species of mouse virus- 
induced interferon cross-reacts with the antiviral activity of murine IF%7. 
Absorption of Antiviral and MAF Activities with Monoclonal Antibodies 
Since rat IgG interfered with the assay system for macrophage activation, monoclonal 
antibodies were coupled to activated CH-Sepharose 4B and the immobilized antibodies 
were used for absorption of interferon activity from ConA supematants. The antiviral 
activity was reduced by 37% of the original sample after 2 hr of end-over-end mixing 
at 37°C (Table 2). Antigen specificity of the absorption was tested by measuring the 
interleukin 2 activity of the fractions in parallel. IL-2 activity was almost completely 
recovered indicating the specificity of the absorption for interferon. No reduction of 
interferon activity was measured when the incubation was performed at room tem- 
perature or in the cold (4°C). In contrast to the virus-induced IFN (12) it was not 
possible to recover antiviral IFN-y activity from the immunosorb-ent because 
TABLE 1 
Neutralization of Antiviral Activity by Monoclonal Antibodies Directed against Interferon 
IFN titer in presence of anti-IFN antibodies” 
0 0.2 Pg 2 Pi? 
ConA lymphokine 384 192 12 
BCG-PPD ‘lymphokine 144 144 36 
Virus-induced IFN 96 48 24 
(1 Purified anti-IFN antibodies were added to the regular interferon assay. 
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TABLE 2 
Estimation of Antiviral and IL-2 Activities after Absorption on Monoclonal 
Anti-IFN Antibodies Fixed on CH-Sepharose 4B 
ConA lymphokine applied 
Eluted fraction 1 
Eluted fraction 2 
Eluted fraction 3 
Eluted fraction 4 
Recovery 







IFN-7 is labile at pH 2 and eluting the immunosorbent after absorptions at 37°C 
with buffers containing high salt concentrations did not result in desorption of antiviral 
activity. These lymphokine preparations were tested before and after absorption on 
coupled antibodies for their capacity to activate macrophages for tumor cytotoxicity. 
Figure 2 shows the activation of macrophages after continuous culture with the lym- 
phokines (Panel A) or the activation by pulsing the cells for just 5 hr (panel B). The 
macrophages were highly cytotoxic when kept at a 1:32 or I:64 dilution of the untreated 
lymphokine for 48 hr or when they were pulsed with a 1: 10 dilution of the ConA 
supernatant. The ability for activation was markedly reduced with the absorbed lym- 
phokine preparation. The dose-response curve was shifted to higher concentrations 
and the continuous presence of a 1: 16 dilution of lymphokine was necessary to induce 
the same degree of cytotoxicity (panel A). No cytotoxic response was induced in this 





I’ 20 10 5 
FIG. 2. Activation of macrophages for tumor cytotoxicity for (A) 48 hr or(B) 5 hr with ConA-induced 
spleen cell supematants before or alter absorption on monoclonal anti-IFN antibodies coupled to CH- 
Sepharose 4B. Cytotoxicity (released [3H]TdR) was estimated at 48 hr and expressed as percentage of total 
incorporated counts. 
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Correlation of Absorption of Antiviral and MAF Activities 
Nonspecific absorption or destruction of interferon activity during the 2-hr mixing 
period could not be excluded, even though another lymphokine, K-2, was almost 
completely recovered (Table 2). Commercial rat IgG was coupled to CH-Sepharose 
4B to estimate the possible effect of nonspecific absorption. ConA supematant was 
absorbed on this material and in a second absorption step (a) on monoclonal anti- 
IFN antibodies or (b) for a second time on rat IgG. Antiviral titers were reduced by 
50% after the first absorption (1950 to 950 units) and again by half after the second 
treatment with coupled rat IgG (400 units). The second absorption on anti-IFN 
antibodies, however, reduced the antiviral titer to the detection limit. The ability of 
these preparations to induce macrophage cytotoxicity is shown in Table 3. The lym- 
phokine absorbed on rat IgG had lost some macrophage activation capacity so that 
a 1: 10 dilution of the once- and a 15 dilution of the twice-absorbed material was 
necessary to reach cytotoxicity values comparable to induction with a 1:80 dilution 
of the original material. The lymphokine that was absorbed on anti-EN antibodies 
after the nonspecific absorption step showed little activating effect even at the highest 
dilution tested ( 1:5). 
DISCUSSION 
In a previous report it was published that monoclonal rat antibodies raised against 
a mixture of highly purified mouse IFN-a and IFN-@ neutralized and bound fibroblast- 
derived antiviral activities of all molecular weight species (12). In this report it is 
shown that antiviral activities from other sources like mitogen- or antigen-induced 
lymphokine preparations were inhibited by these antibodies as well. The specificity 
of the monoclonal antibodies seems to be directed against a rather common structure 
of all interferons. Carbohydrates could be the binding site for the antibodies since 
no peptide sequences common for all IFN species were described. 
Our results show a very close relationship of antiviral titers with MAF activity 
when lymphokines from individual inbred mice were prepared following an identical 
protocol and when they were tested in parallel for the two activities (Fig. 1, r2 = 0.89). 
This is in contrast to recent findings that describe the segregation of macrophage- 
stimulating factors from antiviral activity in ConA-induced supematants of T-cell 
hybridomas (6). However, the source of these supematants, tumor cells, was entirely 
TABLE 3 
Activation of Macrophages for Tumor Cytotoxicity with Lymphokines before and after Absorption 
Lymphokine” 
Nonabsorbed 
Absorbed on rat IgG 
Absorbed twice on rat IgG 






* Macrophages were activated for 5 hr with ConA-induced spleen cell supematants nonabsorbed or 
absorbed on anti-IFN antibodies and/or rat IgG coupled to CH-Sepharose 4B. 
’ Specific cytotoxicity was estimated after 48 hr and expressed as the percentage of total incorporated 
counts. 
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different from the one described in this paper. The possibility exists that there is a 
number of different activating factors depending on the macrophage function tested. 
Also, in the activation of macrophages for tumor cytotoxicity, UN-7 could be an 
essential cofactor which is not required for induction of other macrophage functions. 
The monoclonal rat antibodies used in this study are rather unusual in so far as 
they do not differentiate between different forms of mouse IFNs. However, they are 
unable to bind or neutralize IG2. From this finding and from control absorptions 
on rat IgG coupled to CH-Sepharose 4B it was demonstrated that besides the nonspecific 
loss of antiviral and MAF activity during treatment with the immunosorbent, specific 
absorption of IFN and macrophage-activating factor occurred. The concurrent ab- 
sorption of the two activities indicates two possibilities. (a) Both mediators share at 
least an antigenic site even if they are not identical. This means that MAF in antigen- 
or mitogen-induced lymphokine preparations belongs to the IFN family and is closely 
related to IFN-y. (b) IFN-y is a cofactor necessary to activate macrophages for tumor 
cell lysis in combination with another activating factor and both are contained in 
antigen- or mitogen-induced lymphokines. Which of the two possibilities is true for 
the activating mechanism can only be revealed by utilizing purified and defined 
substances as they might become available by recombinant DNA techniques. 
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